CVRx to Present at the Canaccord Genuity 45th Annual Growth Conference

CVRx, Inc. (NASDAQ: CVRX), a leading commercial-stage medical device company specializing in innovative neuromodulation solutions for patients with cardiovascular diseases, announced that its management team will present at the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025, at 3:00 PM Eastern Time. The presentation will be accessible through a live audio webcast available on the Company’s investor relations page at ir.cvrx.com.

CVRx is renowned for its flagship product, Barostim™, the first FDA-approved medical device leveraging neuromodulation to alleviate heart failure symptoms. The device operates by sending electrical pulses to baroreceptors in the carotid artery wall, aimed at restoring balance within the autonomic nervous system and mitigating heart failure symptoms. Barostim has earned accolades for its groundbreaking treatment approach, securing FDA Breakthrough Device designation and compliance with the EU Medical Device Regulation, which includes holding a CE Mark for applications in heart failure and resistant hypertension across the European Economic Area.

With the ongoing challenges related to cardiovascular diseases, CVRx's focus on innovative solutions is crucial. The presentation at the Canaccord Genuity conference underscores the Company’s commitment to advancing medical technologies that enhance patient outcomes in heart health. As CVRx continues to drive innovation in neuromodulation therapies, industry stakeholders, investors, and healthcare professionals are expected to engage closely with insights shared during the presentation.

For more information about Barostim or to access the webcast, stakeholders can visit CVRx’s website at www.cvrx.com. For investor inquiries, Mark Klausner or Mike Vallie from ICR Westwicke can be contacted, while media inquiries can be directed to Emily Meyers at CVRx.

As CVRx, Inc. prepares to present at the Canaccord Genuity 45th Annual Growth Conference, investors should take this opportunity to evaluate the company's position within the burgeoning cardiovascular medical device sector. With its flagship product, Barostim™, CVRx stands out as a pioneer in neuromodulation therapy for heart failure patients. Given that Barostim is both FDA-approved and possesses CE Mark certification, CVRx has cleared significant regulatory hurdles that position it for further market penetration.

The presentation is likely to provide insights into CVRx's growth strategy, including potential partnerships, market expansion plans, and updates on clinical performance. CVRx's commitment to treating cardiovascular diseases aligns with the increasing demand for innovative medical solutions, especially as cardiovascular conditions remain a leading cause of morbidity and mortality globally. The FDA's Breakthrough Device designation not only highlights the innovation behind Barostim but could also expedite market adoption and reimbursement discussions.

Investors should closely monitor any commentary on clinical trial outcomes and real-world evidence supporting Barostim’s efficacy. Positive updates can catalyze stock performance, given the company’s current visibility and the increasing focus on non-pharmaceutical interventions for chronic diseases.

The timing of the conference also places CVRx in a favorable position as the market anticipates advancements in medical technologies. It's advisable for investors to assess CVRx’s competitive landscape, particularly against emerging technologies and therapies within the cardiovascular domain.

In summary, CVRx presents a compelling investment opportunity, particularly for those with a focus on innovative medical technologies. Monitoring the outcomes from the Canaccord Genuity conference can lead to a more informed investment strategy as CVRx continues to navigate this highly competitive space.